Enfortumab (CAS 1448664-46-7) is a humanized monoclonal antibody that targets Nectin-4, a protein overexpressed in various cancers. It inhibits tumor growth and enhances immune destruction of cancer cells. It can conjugate with MMAE, a microtubule disruptor, to form Enfortumab vedotin, an antibody-drug conjugate (ADC) used for treating locally advanced and metastatic urothelial carcinoma.
Key Features:
- Target Specificity: Binds to Nectin-4 on tumor cells.
- Mechanism of Action: Inhibits tumor growth and boosts immune destruction.
- Conjugate: Conjugated with MMAE for targeted delivery.
Applications:
- Cancer Therapy: Investigated for treating Nectin-4-expressing tumors like urothelial carcinoma.
- Antibody-Drug Conjugates (ADCs): Used for targeted chemotherapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
